QQQ   426.84 (+0.23%)
AAPL   167.83 (-0.10%)
MSFT   411.29 (-0.13%)
META   508.29 (+2.86%)
GOOGL   155.94 (+0.30%)
AMZN   181.82 (+0.30%)
TSLA   150.07 (-3.46%)
NVDA   857.38 (+2.03%)
AMD   156.31 (+1.49%)
NIO   4.05 (+3.58%)
BABA   69.39 (+0.83%)
T   16.19 (+0.43%)
F   12.12 (+0.66%)
MU   113.67 (-2.29%)
GE   156.63 (+0.62%)
CGC   7.84 (+20.80%)
DIS   113.57 (+0.56%)
AMC   2.91 (-2.35%)
PFE   25.33 (-0.35%)
PYPL   62.74 (-0.82%)
XOM   118.79 (+0.13%)
QQQ   426.84 (+0.23%)
AAPL   167.83 (-0.10%)
MSFT   411.29 (-0.13%)
META   508.29 (+2.86%)
GOOGL   155.94 (+0.30%)
AMZN   181.82 (+0.30%)
TSLA   150.07 (-3.46%)
NVDA   857.38 (+2.03%)
AMD   156.31 (+1.49%)
NIO   4.05 (+3.58%)
BABA   69.39 (+0.83%)
T   16.19 (+0.43%)
F   12.12 (+0.66%)
MU   113.67 (-2.29%)
GE   156.63 (+0.62%)
CGC   7.84 (+20.80%)
DIS   113.57 (+0.56%)
AMC   2.91 (-2.35%)
PFE   25.33 (-0.35%)
PYPL   62.74 (-0.82%)
XOM   118.79 (+0.13%)
QQQ   426.84 (+0.23%)
AAPL   167.83 (-0.10%)
MSFT   411.29 (-0.13%)
META   508.29 (+2.86%)
GOOGL   155.94 (+0.30%)
AMZN   181.82 (+0.30%)
TSLA   150.07 (-3.46%)
NVDA   857.38 (+2.03%)
AMD   156.31 (+1.49%)
NIO   4.05 (+3.58%)
BABA   69.39 (+0.83%)
T   16.19 (+0.43%)
F   12.12 (+0.66%)
MU   113.67 (-2.29%)
GE   156.63 (+0.62%)
CGC   7.84 (+20.80%)
DIS   113.57 (+0.56%)
AMC   2.91 (-2.35%)
PFE   25.33 (-0.35%)
PYPL   62.74 (-0.82%)
XOM   118.79 (+0.13%)
QQQ   426.84 (+0.23%)
AAPL   167.83 (-0.10%)
MSFT   411.29 (-0.13%)
META   508.29 (+2.86%)
GOOGL   155.94 (+0.30%)
AMZN   181.82 (+0.30%)
TSLA   150.07 (-3.46%)
NVDA   857.38 (+2.03%)
AMD   156.31 (+1.49%)
NIO   4.05 (+3.58%)
BABA   69.39 (+0.83%)
T   16.19 (+0.43%)
F   12.12 (+0.66%)
MU   113.67 (-2.29%)
GE   156.63 (+0.62%)
CGC   7.84 (+20.80%)
DIS   113.57 (+0.56%)
AMC   2.91 (-2.35%)
PFE   25.33 (-0.35%)
PYPL   62.74 (-0.82%)
XOM   118.79 (+0.13%)
Free Trial
OTCMKTS:DCTHD

Delcath Systems (DCTHD) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)
Free DCTHD Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$4.44
▼
$4.83
50-Day Range
N/A
52-Week Range
$1.22
▼
$63,000.00
Volume
200,583 shs
Average Volume
771 shs
Market Capitalization
$179,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisHeadlines
DCTHD stock logo

About Delcath Systems Stock (OTCMKTS:DCTHD)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

DCTHD Stock News Headlines

March 21, 2024 | gurufocus.com
Director Gil Aharon Acquires 26,882 Shares of Delcath Systems Inc (DCTH)
December 30, 2023 | benzinga.com
Delcath Systems Stock (NASDAQ:DCTH) Insider Trades
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
December 30, 2023 | benzinga.com
Delcath Systems Stock (NASDAQ:DCTH) Dividends: History, Yield and Dates
August 31, 2023 | thestreet.com
Delcath Liver Tumor Data Improve
August 15, 2023 | msn.com
Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy
August 11, 2023 | msn.com
Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA
August 9, 2023 | msn.com
Delcath Systems GAAP EPS of -$0.58 beats by $0.02, revenue of $0.5M misses by $0.24M
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
July 9, 2023 | thestreet.com
Delcath Readies Pivotal Trial Results
June 19, 2023 | forbes.com
Best iPad POS Systems Of 2023
May 24, 2023 | msn.com
HC Wainwright & Co. Reiterates Delcath Systems (DCTH) Buy Recommendation
May 15, 2023 | bbc.co.uk
What is the digestive system?
May 12, 2023 | thestreet.com
Delcath: Safety Questions Behind FDA Delay
March 27, 2023 | finance.yahoo.com
Delcath Systems Announces up to $85 Million Financing
March 27, 2023 | markets.businessinsider.com
Delcath Systems Inc. Q4 Loss increases, misses estimates
March 27, 2023 | finance.yahoo.com
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 27, 2023 | markets.businessinsider.com
Delcath Announces FDA's Acceptance Of NDA Resubmission Of Hepzato Kit
February 16, 2023 | markets.businessinsider.com
Delcath Systems Announces Resubmission Of NDA For Hepzato Kit
December 15, 2022 | gurufocus.com
An Insider Just Bought Shares of Delcath Systems Inc; Could This Stock Be a Value Opportunity?
November 8, 2022 | seekingalpha.com
Delcath Systems slips despite Q3 beat
September 10, 2022 | seekingalpha.com
DCTH Delcath Systems, Inc.
August 10, 2022 | markets.businessinsider.com
Delcath Systems Inc. Q2 Loss increases, misses estimates
July 27, 2022 | markets.businessinsider.com
Delcath Systems to Host Second Quarter 2022 Results
March 15, 2022 | benzinga.com
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
February 4, 2022 | benzinga.com
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver
December 2, 2021 | benzinga.com
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
See More Headlines
Receive DCTHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2016
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:DCTHD
Previous Symbol
NASDAQ:DCTH
CUSIP
N/A
CIK
N/A
Web
www.delcath.com
Phone
212-489-2100
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,220,000.00
Net Margins
-1,546.38%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-343.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.53
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$3.41 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1,036.00) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
40,000
Free Float
N/A
Market Cap
$179,000.00
Optionable
Not Optionable
Beta
-0.03
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Roger G. Stoll Ph.D. (Age 74)
    Chairman of the Board
  • Jennifer K. Simpson Ph.D. (Age 48)
    President, Chief Executive Officer, Director
  • Barbra C. Keck (Age 39)
    Chief Financial Officer, Secretary
  • John Purpura (Age 55)
    Executive Vice President - Global Head of Operations
  • Simon C. Pedder Ph.D. (Age 56)
    Director
  • William Dodge Rueckert (Age 64)
    Independent Director
  • Marco Taglietti M.D. (Age 57)
    Independent Director

Key Competitors

View All Competitors

DCTHD Stock Analysis - Frequently Asked Questions

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) released its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, topping the consensus estimate of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter. During the same period in the previous year, the business earned ($686.00) EPS.

When did Delcath Systems' stock split?

Delcath Systems's stock reverse split on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

This page (OTCMKTS:DCTHD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Paradigm Press
Top 5 AI Stocks to Buy for 2024
Market Moving Trends